i-Base home
Search Menu
  • Home
  • HTB
  • IDWeek 2019

HTB

IDWeek 2019

IDWeek (2019), 2–6 October 2019, Washington DC

18 October 2019. Related: Conference reports.

HIV suppression and safety with ibalizumab at 48 weeks in expanded access

18 October 2019. Related: Conference reports, Antiretrovirals.

Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

18 October 2019. Related: Conference reports, Antiretrovirals.

Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

18 October 2019. Related: Conference reports, Antiretrovirals.

Switching from TDF to TAF linked to higher BMI and cardio risk

18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.

Over half of mostly black US HIV group has NAFLD – and many have NASH

18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.

People taking more medications and women have higher fall risk in older HIV group

18 October 2019. Related: Conference reports, Coinfections and complications, Ageing and life expectancy.

PrEP linked to lower HIV incidence in US, independent of TasP

18 October 2019. Related: Conference reports, HIV prevention and transmission.

  • HTB RSS

Early access

  • Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery 30 January 2023
  • 56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021 27 January 2023
  • Phase 3 Mosaico HIV vaccine efficacy trial stopped early due to lack of benefit 27 January 2023
  • All early access reports

Current issues

  • January 2023
  • December 2022
  • October 2022
  • Back issues

Special report

  • Latest statistics on HIV in the UK: data for 2021 1 December 2022

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook
i-Base on Facebook